A Study of Avutometinib for People With Solid Tumor Cancers
\Multi-Center Phase I Study of Avutometinib (VS-6766), a RAF/MEK Clamp in Combination With Defactinib, a FAK Inhibitor, in Pediatric Patients With Refractory or Recurrent Solid Tumors Harboring Activating MAPK Pathway or NF2 Alterations
Sponsor: Memorial Sloan Kettering Cancer Center
A PHASE1 clinical study on CNS Tumor, Adult and CNS Tumor, Childhood, this trial is actively recruiting participants. The trial is conducted by Memorial Sloan Kettering Cancer Center and has accumulated 6 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
-
May 2025 — Feb 2026 [monthly]
Recruiting PHASE1
-
Nov 2024 — May 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 1 earlier version
-
Nov 2023 — Jul 2024 [monthly]
Recruiting PHASE1
First recorded
Oct 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .